Most people being treated for mental health conditions such as anxiety or depression typically use a mix of just two ...

Health Canada has approved zuranolone, sold under the brand name Zurzuvae, as the first oral treatment for moderate to severe ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for TRN-257, a controlled-release, low-sodium oxybate product, for the treatment of c ...

A new study shows that balanced neural inhibition in the hippocampus is crucial for recognition memory, the ability to remember objects we’ve recently encountered.

A new study has revealed that neural inhibition and balanced neural activity in a specific area of the brain is required for ...

Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026 Topline results on track for the second quarter of 2026 SALT LAKE CITY, ...

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience ...

With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important ...

Health Canada has approved the first drug designed to treat postpartum depression. Zuranolone, sold under the brand name ...